Navigation Links
Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease
Date:4/15/2009

E: This press release contains forward-looking statements, including statements regarding the timing of: initiation of clinical studies, filing of an NDA for Dimebon, the presentation of data with respect to Dimebon and the receipt of milestone payments as well as the extent of future expected financial results, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2008 filed March 16, 2009, with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.


'/>"/>
SOURCE Pfizer Inc; Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
2. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. MannKind Addresses Pfizers Announcement Regarding Exubera
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
9. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
10. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
11. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
(Date:9/18/2014)... Sept. 18, 2014  LABSCO, the leading ... and products to hospitals, physician office laboratories ... amended distributorship agreement with Sysmex America.  This ... instruments, including the Sysmex XS-1000 i ™, ... and XN-Series Automated Hematology Analyzers. ...
(Date:9/18/2014)... -- According to the new research ... Warming & Cooling), Application (Acute & Perioperative Care, ... & Paramedical Staff) - Global Forecasts & Trends ... global Temperature Management Market over the forecast period ... to reach $2.5 Billion by 2019 at CAGR ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4
... EyeScience(TM) ( www.eyescience.com ) announced today that ... and Dry Eye Formula(TM) are the only ... from their offices and through mass market retail. This announcement ... growing demand for the most complete eye vitamins available for ...
... (Nasdaq: HOLX ) today announced that Jack Cumming, Chairman, ... London on Tuesday, December 1, 2009, at 11:15am (GMT). ... audio webcast of Hologic,s investor presentation on the investor section ... An archive of the presentation will be available for replay ...
Cached Medicine Technology:EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 2EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 3
(Date:9/19/2014)... Business Insider Australia Rates Appy Pie as a ... Appy Pie was also listed as one of the ... Yahoo . , Appy Pie a leading cloud based DIY ... minutes and it requires no coding knowledge or previous experience ... mobile operating systems, the apps created using their platform are ...
(Date:9/19/2014)... CA (PRWEB) September 19, 2014 The ... a special promotion for new patients. Throughout the month of ... dental exam with dental X-rays for just $69. A complimentary ... patients to get their teeth and gums checked and meet ... are among the best ways to protect oral health. According ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, Sept. 18, ... got a flu shot last year, so U.S. health officials ... vaccinated for the coming flu season. "It,s really unfortunate ... flu they could get," said Dr. Thomas Frieden, director of ... morning news conference. The result is lost days from ...
(Date:9/19/2014)... Quincy Bioscience is pleased to announce ... private practice in Mequon, Wis., is presenting data ... adults with mild memory problems at the ... conference on Sept. 19-20 in Hollywood, Fla. ... of the jellyfish protein apoaequorin-containing supplements. Prevagen Professional ...
(Date:9/19/2014)... LENEXA, Kan. (PRWEB) September 19, 2014 ... dedicated exclusively to healthcare providers, has been retained to ... for St. John’s Episcopal Hospital in Far Rockaway, N.Y. ... B. E. Smith has recently placed more than 900 ... Hospital is a faith-based, full service community hospital serving ...
Breaking Medicine News(10 mins):Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Encino Esthetic Dental Group is Now Offering a Special Promotion for New Patients 2Health News:Almost Everyone Needs a Flu Shot: CDC 2Health News:Almost Everyone Needs a Flu Shot: CDC 3Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 3
... to the brain can be devastating. When brain cells die, ... glutamate floods the surrounding areas, overloading the cells in its ... swathes of tissue. ,Glutamate is always present ... gaps between cells. But when this chemical is released by ...
... infections in parts of Cambodia is being extended to an ... 40,000 residents, an expert said. ,Although malaria-infected mosquitoes ... the real source of the disease is people, some of ... time without showing clear symptoms. ,Moheli island, the ...
... responsible for staphylococcus infections can kill infected patients in ... by the name of PVL or otherwise called Panton ... and harm the healthy tissue as well. ... infections. This is normally found in the skin or ...
... showed reasonable resistance to Tamiflu, an antiviral, in two Egyptians who ... the medical community. ,The report also states that the ... in 2005. The occurrence of this strain in Egypt reveals that ... Tamiflu by the birdflu virus has not changed the WHO stance ...
... Center researchers have identified an approach to enhance the ... shown impressive efficacy in the treatment of chronic myelogenous ... a cancer of the bone marrow caused by a ... common forms of leukemia. Imatinib mesylate (Gleevec) is a ...
... is probing the link between breast density and its implication ... novel study on 1,112 women has brought to the fore, ... with dense breasts. The study revealed that, those with dense ... breast cancer, compared to women with fatty tissue in the ...
Cached Medicine News:Health News:New Method May Treat Brain Injuries 2Health News:Chinese Scientists Take Malaria Fight to Africa 2Health News:New Strategy for the Treatment of CML 2Health News:New Strategy for the Treatment of CML 3
Duckbill type, sharp. 3 mm x 8 mm curved blade. Octagonal handle....
10 mm wide tip....
9 mm wide tip. 35 mm from angle to tip....
Designated most popular model or size. 4 mm wide tip....
Medicine Products: